<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to hydroxyurea administration in patients with sickle cell disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to hydroxyurea administration in patients with sickle cell disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Approach to hydroxyurea administration in patients with sickle cell disease</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Laboratory testing</td> <td class="subtitle1">Dosing</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Initiating hydroxyurea therapy</td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>CBC with differential and PLT </li> <li>Reticulocyte count </li> <li>Quantitative measure of HbF (eg, HPLC) </li> <li>Kidney and liver function tests </li> <li>Pregnancy test for females of childbearing potential </li> </ul> </td> <td> <ul> <li>Infants younger than 1 year: Start at 15 mg/kg daily </li> <li>Older children, adolescents and adults with CrCl &gt;60 mL/min: Start at 20 mg/kg daily </li> <li>Patients with chronic kidney disease: Start at half the normal dose (eg, 5 to 10 mg/kg daily) </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Transitioning from chronic prophylactic transfusion to hydroxyurea therapy</td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>All baseline testing listed above for starting hydroxyurea </li> <li>Every month: CBC with differential and PLT, ANC, ARC, HbF, kidney and liver function tests </li> </ul> </td> <td> <ul> <li>Wean transfusion by lowering the post-transfusion target hemoglobin to 11.5 g/dL </li> <li>Increase hydroxyurea dose every 8 weeks by 5 mg/kg daily to a maximum of 35 mg/kg or 2500 mg daily using MTD parameters below </li> <li>Continue weaning transfusions. Reduce the target post-transfusion hemoglobin to 11 g/dL at 2 months and to 10.5 g/dL at 4 months </li> <li>Discontinue transfusions when stable MTD is reached; initiate phlebotomy or continue chelation therapy if there is transfusional iron overload </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Titrating hydroxyurea to MTD*</td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>CBC with differential and reticulocyte count at least every month </li> </ul> </td> <td> <p>Criteria for dose escalation (must meet <strong>all</strong> of the following): </p> <p>• ANC &gt;1000/microL </p> <p>• ARC &gt;100,000/microL </p> <p>• PLT &gt;150,000/microL </p> <p>Criteria for MTD (<strong>any</strong> of the following with no evidence of toxicity): </p> <p>• ANC 1500 – 3000/microL </p> <p>• ARC 80 – 100,000/microL </p> <p>• PLT 80,000 – 100,000/microL </p> <p>Criteria for toxicity (<strong>any</strong> of the following): </p> <p>• ANC &lt;1500/microL (&lt;1000/microL if &lt;2 years of age) </p> <p>• ARC &lt; 80,000/microL </p> <p>• PLT &lt;80,000/microL </p> <p>Monitor CBCs over at least two months after each dose increase to determine if MTD has been reached or further dose escalation is indicated.</p> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Chronic maintenance therapy</td> </tr> <tr> <td class="indent1"> <ul> <li>CBC with differential, PLT, and reticulocyte count every two to three months </li> <li>Creatinine and liver function tests every 6 to 12 months </li> <li>Ferritin and HbF once per year </li> <li>Urine pregnancy tests as appropriate </li> <li>For hematologic toxicity, weekly CBC until resolution </li> </ul> </td> <td> <ul> <li>Reinforce importance of dose adherence </li> <li>Reinforce need for contraception if appropriate<sup>¶</sup> </li> <li>For hematologic toxicity, hold dose until recovery into target range and reinitiate at the same or lower dose (eg, previous dose reduced by 2.5 mg/kg/day), depending on the severity and duration of toxicity </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">For infants and young children taking a liquid formulation, the dose can be rounded to the nearest 2.5 mg/kg. For individuals able to take pills, the dose is rounded off to the nearest pill size. All patients of childbearing potential (male and female) should be counseled about the need for contraception while taking hydroxyurea. Six months of therapy at MTD may be required before a response is seen. If there is no apparent response, it may be appropriate to assess MCV and HbF; however, some patients who are taking the medication correctly will not have a response, and lack of an increase in MCV or HbF is not an indication to discontinue therapy if clinical benefit is seen. Refer to UpToDate topics on SCD and hydroxyurea use for information about appropriate indications and additional details of administration.</div><div class="graphic_footnotes">SCD: sickle cell disease; CBC: complete blood count; PLT: platelet count; HbF: hemoglobin F; HPLC: high performance liquid chromatography; ANC: absolute neutrophil count; ARC: absolute reticulocyte count; MTD: maximum tolerated dose; CrCl: creatinine clearance; MCV: mean cell volume.<br/>* Infants and young children with lower baseline ANCs can tolerate an on-therapy ANC as low as 1000/microL. Refer to UpToDate for a discussion of the optimal number of parameters to monitor.<br/><sup>¶ </sup>Applies to males and females.</div><div class="graphic_reference">Adapted from:

<ol>
<li>Ware RE. Optimizing hydroxyurea therapy for sickle cell anemia. Hematology Am Soc Hematol Educ Program 2015; 2015:436.</li>
<li>Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.</li>
</ol></div><div id="graphicVersion">Graphic 107002 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
